MERCALIS
LIVE

Serial Number

97916626

Owner

TrialCard Incorporated

Attorney

Larry L. Coats

First Use Date

Sep 20, 2023

Filing Date

May 2, 2023

Add to watchlist:

No watchlists yet
View on USPTO

MERCALIS Trademark

Serial Number: 97916626 • Registration: 7892673

MERCALIS is a trademark filed by TrialCard Incorporated on May 2, 2023. The trademark is classified under Class 36 (Insurance & Financial), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

TrialCard Incorporated (22 trademarks)

6501 Weston Parkway
Cary, NC 27513

Entity Type: 03

MERCALIS INC. (19 trademarks)

2250 PERIMETER PARK DRIVE
MORRISVILLE, NC 275608893

Entity Type: 03

Trademark Details

Filing Date

May 2, 2023

Registration Date

August 12, 2025

First Use Anywhere

September 20, 2023

First Use in Commerce

September 20, 2023

Published for Opposition

August 13, 2024

Goods & Services

Outbound healthcare provider engagement services provided on behalf of pharmaceutical manufacturers, namely, providing podcasts, seminars, workshops, and virtual and in-person presentations for educational purposes in the field of diseases, pharmaceutical brands, and affordable healthcare options

Payment services, namely, reimbursement payment processing in the field of pharmaceutical financial assistance programs and loyalty program payment processing services provided on behalf of pharmaceutical manufacturers for the purpose of delivering benefits to patients enrolled in pharmaceutical manufacturer-sponsored financial assistance programs; Pharmacy benefit manager (PBM) accumulator mitigation services and detecting claim activity indicative of a pharmacy benefit manager attempting to abuse the use of co-pay cards by not applying amounts paid by clients towards the patient's deductible or annual out-of-pocket expense; Anti-kickback and risk mitigation services for the pharmaceutical industry, namely, antikickback compliance services for assuring that patients who have full or partial federally funded drug coverage are excluded from utilizing co-pay cards

Business management and administration of pharmacy reimbursement programs; Managing and administering the distribution of prescription pharmaceutical samples to physicians and patients for pharmaceutical manufacturers; Business management and administration of patient co-pay reimbursement programs on behalf of pharmaceutical manufacturers; Business management and administration of financial assistance programs that provide patients with access to affordable medicine, namely business management and administration of enrollment and reimbursement programs for the purchase of medication and generally facilitating access to medications; Business management and administration of patient support programs for pharmaceutical manufacturers; Business management and administration of patient engagement programs for pharmaceutical manufacturers; Business management and administration of formulary, patient, and payer policy information for pharmaceutical, medical device, and diagnostic manufacturers; Business management and administration of educational engagements for Health Care Providers, namely, business management and administration of efforts to educate healthcare providers on medications, disease status and standard of care; Management of the distribution of clinical trial medication and supplies on behalf of pharmaceutical manufacturers; Providing business marketing information, namely, tracking pharmaceutical promotional programs for pharmaceutical manufacturers and evaluating and determining their effectiveness; Data management services in the field of pharmaceutical patient safety, namely, collecting adverse product events data, storing the data, and reporting collected adverse product events data; Outbound healthcare provider engagement services provided on behalf of pharmaceutical manufacturers, namely, promoting awareness of diseases, pharmaceutical brands, and treatment affordable options; Outbound healthcare provider engagement services provided on behalf of pharmaceutical manufacturers, namely, marketing services in the nature of promotion of pharmaceutical manufacturers and disease treatment options via social media; Business information services, namely, tracking payer coverage policies and related documentation and providing life sciences clients access to such in order to enhance their market access strategies and patient support programs; Life science business strategy consulting services for assisting clients with commercial assessments, corporate and portfolio strategy, new product planning and commercialization support, and pricing and market access insights; Business assistance services, namely, enrolling patients of pharmaceutical manufacturers into support programs that enable patients to view, track, and manage the support program wherein the patient support program provides pharmaceutical consumer product information, payer coverage status updates, and providing business information regarding access to enrollment and reimbursement programs for the purchase of medications; Providing business information and news to the pharmaceutical and life sciences industries on legislative and regulatory developments as it impacts and relates to the pharmaceutical and life sciences industries within the copay or patient affordability space

Pharmacy benefit fraud monitoring, namely, investigation services related to pharmacy benefit insurance claims

Quality assurance and quality control patient claim services for monitoring paid claims to patients from insurance or pharmaceutical entities to insure that specific business rules are being correctly applied to patient claims; Pharmacovigilance services for others, namely, scientific research and analysis pertaining to adverse events and product quality complaints regarding pharmaceutical products, assessment of risks presented by certain pharmaceutical products or combinations thereof, and product safety testing and consultation related thereto in the field of pharmaceuticals; Pharmacovigilance services for others, namely, monitoring the quality of efficacy of pharmaceutical preparations; Providing online non-downloadable software for patient support services, namely, for enrolling patients of pharmaceutical manufacturers in support programs that enables the patients to view, track and manage the support program wherein the patient support program provides pharmaceutical product and medication education, medication adherence support, visibility into medication delivery and case status, clinical support services including injection and product educational training, access to financial assistance programs, payer coverage status updates, patient engagement services and reminders and notifications

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 12, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 12, 2025 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jul 23, 2025 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jul 23, 2025 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Jul 18, 2025 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jul 16, 2025 AITU
USE AMENDMENT FILED
Apr 3, 2025 IUAF
TEAS STATEMENT OF USE RECEIVED
Apr 3, 2025 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 8, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 13, 2024 NPUB
PUBLISHED FOR OPPOSITION
Aug 13, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 24, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 11, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 10, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 10, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 10, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 5, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jul 5, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jul 5, 2024 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Jul 3, 2024 ZZZX
ASSIGNED TO EXAMINER
Jun 9, 2024 DOCK
ASSIGNED TO EXAMINER
May 15, 2024 DOCK
WITHDRAWN FROM PUB - OG REVIEW QUERY
May 14, 2024 PBCR
APPROVED FOR PUB - PRINCIPAL REGISTER
May 1, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
May 1, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 1, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
May 1, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 1, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 25, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 25, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 25, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 29, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jan 29, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jan 29, 2024 CNRT
ASSIGNED TO EXAMINER
Jan 29, 2024 DOCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Nov 15, 2023 ASGN
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 31, 2023 NWOS
NEW APPLICATION ENTERED
May 5, 2023 NWAP